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Abstract
Objective—This study examined HIV superinfection (HIV SI) in HIV-infected women 
postpartum, and its association with mother-to-child transmission (MTCT).
Design—Plasma samples were obtained from HIV-infected women who transmitted HIV to their 
infants after 6 weeks of age (transmitters, n=91) and HIV-infected women who did not transmit 
HIV to their infants (non-transmitters, n=91). These women were originally enrolled in a 
randomized trial for prevention of MTCT of HIV in Malawi (PEPI-Malawi).
Methods—Two HIV genomic regions (p24 and gp41) were analyzed by next generation 
sequencing (NGS) for HIV SI. HIV SI was established if the follow-up sample contained a new, 
phylogenetically distinct viral population. HIV SI and transmission risk were examined by 
multiple logistic regression, adjusted for PEPI study arm, baseline viral load, baseline CD4 cell 
count, time to resumption of sex, and breastfeeding duration.
Results—Transmitters had lower baseline CD4 cell counts (p=0.001) and higher viral loads 
(p<0.0001) compared to non-transmitters. There were five cases of SI among transmitters [rate of 
SI=4.7/100pys person year (pys)] compared to five cases among the non-transmitters (rate of 
SI=4.4/100pys; p=0.78). HIV SI was not associated with increased risk of post-natal MTCT of 
HIV after controlling for maternal age, baseline viral load and CD4 cell count (adjusted odds 
ratio=2.32, p=0.30). Longer breastfeeding duration was independently associated with a lower risk 
of HIV SI after controlling for study arm and baseline viral load (p=0.05).
Conclusions—There was a significant level of HIV SI in women postpartum, but this was not 
associated with an increased risk of MTCT via breastfeeding.
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HIV superinfection (SI) occurs when an HIV-infected individual is infected with a new, 
phylogenetically distinct HIV strain [1]. HIV SI has been demonstrated in multiple cohorts 
around the world, and occurs at varying rates that can be similar to the corresponding 
primary HIV incidence rate in the population, although this has not been observed in all 
studies [2-7]. Rates of HIV SI appear to be higher in populations at increased risk of primary 
HIV infection, such as female sex-workers [8]. HIV SI can cause temporary and sustained 
increases in viral load, which could increase the risk of HIV transmission to other 
individuals [4, 9, 10]. Examining the role of SI and sexual transmission in HIV discordant 
sexual partnerships is difficult since it is often impossible to establish if the SI event 
occurred prior to the subsequent transmission, or vice versa [7]. In contrast, studying SI in 
the context of MTCT of HIV through breastfeeding is simpler, because there is no question 
about the directionality of SI and subsequent transmission, and because there are fewer 
confounding behavioral factors.
The Post-Exposure Prophylaxis of Infants trial in Malawi (PEPI-Malawi, 2004-2009) 
demonstrated that the risk of MTCT of HIV via breastfeeding was significantly reduced by 
providing infants an extended regimen of nevirapine or nevirapine plus zidovudine 
prophylaxis up to age 14 weeks, compared to infants who received a short regimen for 
prophylaxis (single dose nevirapine with one week of zidovudine) [11]. Several studies in 
sub-Saharan Africa, including Malawi, have demonstrated that postpartum women are at 
increased risk of HIV infection, particularly at the time when sexual activity is resumed 
[12-14]. Genital tract infections and risk behaviors were the main factors associated with 
HIV acquisition postpartum. It is not known if there is an increased risk of HIV SI in HIV-




Women provided written informed consent for participation in the PEPI-Malawi trial 
(NCT00115648). The study was approved by the institutional review boards in Malawi and 
the United States. [11].
Study Population
A detailed description of the PEPI-Malawi trial has been described previously [11]. Briefly, 
eligible HIV-infected pregnant women presenting for either antenatal or delivery services in 
Blantyre, Malawi were offered participation in the PEPI-Malawi trial. Infants who were 
HIV-uninfected at birth were then randomized to either a control regimen (single-dose 
nevirapine and one week of zidovudine, the standard of care at the time) or the control 
regimen plus one of two extended antiretroviral (ARV) prophylaxis regimens (daily 
nevirapine, or daily nevirapine plus zidovudine) for up to 14 weeks of age [11]. Women 
whose infants tested HIV-negative at six weeks of age and HIV-positive by 24 months of 
age were identified as transmitters. Transmitters were included in the current study if they 
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had plasma samples available at both baseline and at the time of their infant's HIV diagnosis, 
or at a later time point up to age 24 months (n=120). Transmitters were included in the 
analysis if their samples were successfully amplified and analyzed by next generation 
sequencing (NGS), for at least one genomic region of both samples screened (n=91). 
Transmitters were initially matched as a group on study arm and duration of follow-up to 
women who did not transmit HIV to their infants (non-transmitters, n=454). Appropriate 
baseline and follow-up samples according to length of follow-up were available for 164 non-
transmitters. Amplification and NGS of at least one genomic region of both samples was 
successful for 91 non-transmitters who were included in the current study. HIV viral load 
and CD4 cell count testing were performed on baseline samples in the PEPI-Malawi trial 
[15].
HIV superinfection analysis
Maternal plasma samples were analyzed using NGS to identify HIV SI, as described 
previously [1, 8]. Briefly, HIV RNA was extracted from 140μL plasma, reverse-transcribed, 
and amplified using a nested-polymerase chain reaction (PCR) to produce amplicons 
corresponding to portions of the viral p24 (~390 basepairs) and gp41 (~324 basepairs) 
genomic regions. Samples that were successfully amplified for both study visits (baseline 
and follow-up) in at least one region were sequenced using the 454 DNA Sequencing 
platform as previously described, with adjustments to use a 2-region format (Roche, 
Branford, CT) [1, 2, 8]. Pools of samples were processed using emPCR Amplification 
Manual-Lib-L-LV – June 2013 (Roche Branford, CT) using 25% of the recommended 
amplification primer amount and a 0.2 copy-per-bead ratio [1].
The resulting sequencing reads were analyzed and similar sequences were combined into a 
single consensus sequence. Consensus sequences that encompassed a cluster of at least ten 
individual, near-identical sequence reads were determined [1, 2]. In order to remove any 
residual contaminating sequences a representative sequence from all distinct viral 
populations for each sample run in a given NGS sequencing plate were combined in a 
neighbor-joining tree, and any micro-contamination or spillover sequences that localize with 
another unrelated sample are removed. The clean sequences from the women's two sample 
time points were analyzed in a neighbor-joining tree with a variety of HIV reference 
sequences containing representative sequences of the major African subtypes (n=23 for p24 
and n=25 for gp41) as well as a collection of sequences from Malawi (n=13 for p24, and 
n=30 for gp41).
HIV SI was defined when the follow-up sample yielded two or more distinct consensus 
sequences forming a phylogenetic cluster that was distinct from the consensus sequences in 
the baseline sample, and were of adequate genetic distance from the baseline sequences to 
rule out evolutionary drift [1]. Genetic distance cut-off for HIV SI was a rate ≥0.59% per 
year for the p24 region, or ≥0.98% per year for the gp41 region, which is equal to the mean 
plus twice the standard deviation of the intra-person viral divergence from a previous 
analysis[1]. Any SI events were re-amplified and sequenced in a separate reaction to 
confirm SI [2]. The consensus sequences for gp41 and p24 are available upon request 
(aredd2@jhmi.edu).
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Differences between women in the transmitter and non-transmitter groups were compared 
using Fisher's exact test for categorical variables. For continuous variables, medians and 
interquartile ranges (IQR) are reported and non-parametric tests were used for comparisons 
since data were not normally distributed (Wilcoxon Rank Sum/Kruskal-Wallis). Similar 
methods were used to compare characteristics across three groups of non-transmitters to 
assess for possible bias: a) all non-transmitters, b) non-transmitters selected for sequencing, 
c) non-transmitters with samples and NGS results available for analysis. The association 
between HIV SI and transmission risk was examined by multiple logistic regression adjusted 
for maternal age, baseline log10 viral load and baseline CD4 cell count. Rates of SI were 
calculated as confirmed SI events divided by person years of follow-up. Incidence rate ratios 
(IRR) were estimated using Stata 11. Risk factors for HIV SI were examined by logistic 
regression; PEPI study arm, baseline CD4 cell count and breastfeeding duration were 
included in the multivariate model.
Results
Characteristics of the 91 non-transmitter women included in this analysis were not 
significantly different from those of all other non-transmitting women enrolled in the PEPI-
Malawi trial (Table 1). Non-transmitters analyzed for HIV SI had significantly higher 
baseline CD4 cell counts (p=0.001), lower baseline HIV viral loads (p<0.0001), and slightly 
shorter breastfeeding duration than transmitters (n=91, p=0.048, Table 1). Transmitters and 
non-transmitters included in the analysis did not differ significantly in age or time to 
postpartum resumption of sexual activity (Table 1).
Five cases of SI were identified in women from the transmitter group compared to five in 
the non-transmitter group (p=1.0, Table 1, Figure 1, and supplementary figure 1). Three of 
the ten SI events involved complete replacement of the original strain by the new 
superinfecting strain [2]. The rates of SI in the transmitters and non-transmitters were 
4.7/100 person years (pys) [95% confidence interval (CI)=1.5-11.0] and 4.4/100 pys (95% 
CI=1.4-10.3), respectively (IRR=1.1, 95% CI=0.3-4.7; p=0.92). As part of the original trial 
women were asked if they had a sexual partner (excluding husband) since their last visit, and 
if they were using condoms with that partner. Of the women examined here, 180 reported no 
extra sexual partners, with two women having missing data; therefore no association was 
found between extra-partners and risk of SI.
Maternal HIV SI did not increase the odds of MTCT of HIV via breast-feeding when 
controlling for maternal age, baseline CD4 cell count, and baseline viral load (adjusted 
OR=2.32, 95% CI=0.47-11.47; p=0.30, Table 2). In univariate and adjusted models, longer 
breastfeeding duration was borderline significantly associated with a lower risk of HIV SI 
after controlling for baseline viral load and PEPI study arm (p=0.05, Table 3).
Discussion
HIV SI has been observed in multiple populations and settings, and is associated with 
underlying HIV risk in the same populations [4]. Postpartum women in Malawi have been 
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shown to be at increased risk for primary HIV infection [12]. The rate of HIV SI observed 
among HIV-infected women in the PEPI-Malawi trial corroborates this risk of exposure and 
vulnerability to HIV primary infection in the postpartum period. The study also 
demonstrated a significant association of maternal viral load with MTCT of HIV, which is a 
well-established risk factor. Longer breastfeeding duration was associated with decreased 
odds of SI, although the mechanism for this relationship is not clear. A previous analysis of 
this population found that women who breastfed had a 48% lower likelihood of resuming 
sexual activity early, which may be associated with the lower risk of SI [16]. Additionally, 
in at least four of the transmission events the mother's reported cessation of breastfeeding 
prior to the period when their child was infected. It should be noted that this study examined 
viral populations from the mothers only, and does not address what viral strain was 
transmitted to their infants.
One limitation of this study was that the transmitter group was selected for analysis based on 
the assumption that MTCT would be associated with SI. While this association was not seen 
in this population, inclusion of a significant proportion of transmitters in this study (50% of 
the women assessed for SI) may have biased the overall rate of SI. Another limitation of this 
study is that for five of the women who appeared to be superinfected a sample available 
post-SI was not possible because their SI event was detected in samples collected at their 
last study visit. Additionally, this study was a secondary analysis of a well-studied cohort of 
patients and therefore in the other five cases later samples were not readily available. These 
facts limited the ability to verify the SI events in a second sample post-SI, and means that in 
the cases of full replacements a sample mix-up cannot be ruled out. However, all SI events 
were re-amplified to confirm SI, which should help address this concern. The limited sample 
volume for these samples also did not allow to perform HIV viral load analysis on the 
follow-up samples, although the enrollment viral load was previously measured as part of 
the original trial.
Case studies, as well as a cohort study of Kenyan female bar workers, have demonstrated 
that HIV SI is associated with both transient and persistent increases in HIV viral load, one 
of the main drivers of HIV transmission [4, 9, 10, 17, 18]. It is unknown what role HIV SI 
has on MTCT or sexual transmission, but given the effect it has on viral load, it is possible 
that SI could temporarily increase the infectiousness of the individual. However, it is 
difficult to establish the directionality and relationship of SI and transmission events in the 
setting of sexual transmission [4, 7]. This issue is not relevant in MTCT of HIV, since 
transmission only occurs vertically. In this study, although the rate of SI was significant in 
women after delivery, SI was not associated with an increased risk of MTCT of HIV 
through breastfeeding. It should be pointed out that this study might have been 
underpowered to detect this association.
The current best clinical practice in Africa for prevention of MTCT of HIV is to provide all 
HIV-infected mothers with highly active ARV therapy (ART) during pregnancy and to 
continue ART for the rest of their lives (i.e., Option B+)[19]. Continued provision of ART 
after delivery should reduce the risk of HIV SI. The high rates of SI observed in this study 
support the use of Option B+ moving forward, since it is likely to reduce the risk of MTCT 
and potential adverse effects of HIV SI, such as higher viral loads.
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Clinical and trial data by woman for the ten cases of HIV superinfection were identified. 
Five cases from the transmitting women (Cases #1-5) and five cases from the non-
transmitters (Cases #6-10) are shown (corresponding phylogenetic trees are shown in 
supplemental figure 1). Grey arrow: indicates duration of breastfeeding based on self-report; 
Black arrow: indicates the visit where infant was diagnosed with HIV; Red arrow: indicates 
the visit HIV superinfection was detected; Blue arrow: indicates the visit the woman 
reported resumption of sexual activity. Abbreviations: Inf: Infant; SI: superinfection; SR: 
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sex resumed; wk: weeks; mo: months; CD4: CD4 cell count (expressed as cells/mm3); n/a: 
not applicable; VL: HIV viral load (expressed as log10copies/mL).
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Table 2
Association between maternal superinfection (SI) and mother-to-child transmission of HIV via breastfeeding.
Unadjusted Adjusted
Factors n/N OR (95% CI) p-value OR (95% CI) p-value
Superinfection 1.00 0.30
No (ref) 172/182 1 1
Yes 10/182 1.66 (0.52-5.27) 2.32 (0.47-11.47)
Maternal age 0.44 0.53
17-24 yrs (ref) 68/182 1 1
≥25 yrs 114/182 1.32 (0.73-2.42) 0.79 (0.37-1.66)
PEPI study arm 1.00
Control (ref) 56/182 1
Intervention 126/182 1.00 (0.51-1.97)
Baseline CD4 cell count 0.002 0.11
<250 cells/μl (ref) 49/172 1 1
≥250 cells/μl 123/172 0.33 (0.15-0.69) 0.50 (0.22-1.16)
Baseline log10 VL 0.001 0.004
<4 log10 copies (ref) 55/157 1 1
≥4 log10 copies 102/157 3.44 (1.64-7.43) 3.06 (1.44-6.54)
Abbreviations: N: total number of individuals; n: number of individuals with given trait; OR: odds ratio; CI: confidence intervals; PEPI: Post-
exposure Prophylaxis of Infants in Malawi trial; VL: viral load.
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Table 3
Association between selected risk factors and superinfection
Unadjusted Adjusted
Factors n/N OR (95% CI) P-value OR (95% CI) P-value
Maternal age 0.86 - -
17-24 yrs 68/182 1
≥25 yrs 114/182 0.89 (0.24-3.27)
Parity 0.84 - -
1-2 60/182 1
>2 122/182 1.16 (0.29-4.64)
PEPI study arm 0.19 0.45
Control 56/182 1 1
Intervention 126/182 0.42 (0.12-1.52) 0.54 (0.11-2.71)
Baseline CD4 cell count, 100 cells/μL 0.97 (0.69-1.34) 0.84
Baseline log10 VL 0.46 (0.17-1.24) 0.12 0.40 (0.13-1.19) 0.10
Time to resumption of sexual activity, mos 0.90 (0.73-1.11) 0.32
BF duration, mos 0.78 (0.62-0.99) 0.04 0.75 (0.56-1.00) 0.05
Abbreviations: N: total number of individuals; n: number of individuals with given trait; OR: odds ratio; CI: confidence intervals; PEPI: Post-
exposure Prophylaxis of Infants in Malawi trial; VL: viral load; yrs; years; mos: months; BF: breastfeeding.
AIDS. Author manuscript; available in PMC 2016 July 31.
